Replimune Group Future Growth
Future criteria checks 2/6
Replimune Group is forecast to grow earnings and revenue by 21.6% and 58.6% per annum respectively while EPS is expected to grow by 27.4% per annum.
Key information
21.6%
Earnings growth rate
27.4%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | 58.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 22 Dec 2024 |
Recent future growth updates
Recent updates
Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch
Nov 29Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Nov 23
Replimune: Strong Data In A Highly Differentiated Space
Sep 03Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?
Aug 16Replimune: Continuing To Justify The Bear Thesis (For Now)
May 22Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Feb 06Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer
Jan 23Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)
Dec 25Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Jul 13Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?
Apr 05A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Jan 06Replimune secures $200M term loan
Oct 07Replimune: Recent Developments Strengthen Bull Thesis
Aug 12Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?
Aug 06Replimune Group GAAP EPS of -$0.78 misses by $0.15
Aug 04Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jun 24We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate
Apr 04Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth
Dec 16Replimune: In The 'Buy Zone' Again
Oct 01Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)
Sep 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 109 | -195 | -216 | N/A | 3 |
| 3/31/2026 | 40 | -227 | -196 | -147 | 5 |
| 3/31/2025 | 8 | -222 | -201 | -156 | 7 |
| 9/30/2024 | N/A | -213 | -188 | -181 | N/A |
| 6/30/2024 | N/A | -220 | -193 | -186 | N/A |
| 3/31/2024 | N/A | -216 | -191 | -185 | N/A |
| 12/31/2023 | N/A | -210 | -176 | -172 | N/A |
| 9/30/2023 | N/A | -199 | -157 | -154 | N/A |
| 6/30/2023 | N/A | -182 | -145 | -143 | N/A |
| 3/31/2023 | N/A | -174 | -130 | -128 | N/A |
| 12/31/2022 | N/A | -157 | -121 | -118 | N/A |
| 9/30/2022 | N/A | -147 | -111 | -108 | N/A |
| 6/30/2022 | N/A | -133 | -100 | -97 | N/A |
| 3/31/2022 | N/A | -118 | -85 | -82 | N/A |
| 12/31/2021 | N/A | -108 | -78 | -76 | N/A |
| 9/30/2021 | N/A | -100 | -72 | -70 | N/A |
| 6/30/2021 | N/A | -91 | -66 | -65 | N/A |
| 3/31/2021 | N/A | -81 | -64 | -61 | N/A |
| 12/31/2020 | N/A | -75 | -59 | -57 | N/A |
| 9/30/2020 | N/A | -70 | -66 | -59 | N/A |
| 6/30/2020 | N/A | -61 | -69 | -62 | N/A |
| 3/31/2020 | N/A | -53 | -67 | -61 | N/A |
| 12/31/2019 | N/A | -43 | -62 | -55 | N/A |
| 9/30/2019 | N/A | -35 | -49 | -46 | N/A |
| 6/30/2019 | N/A | -30 | -35 | -32 | N/A |
| 3/31/2019 | N/A | -31 | -28 | -25 | N/A |
| 12/31/2018 | N/A | -31 | -24 | -24 | N/A |
| 9/30/2018 | N/A | -28 | -20 | -20 | N/A |
| 6/30/2018 | N/A | -26 | N/A | -17 | N/A |
| 3/31/2018 | N/A | -20 | N/A | -16 | N/A |
| 12/31/2017 | N/A | -17 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: REPL's revenue (58.6% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: REPL's revenue (58.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if REPL's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 23:31 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Replimune Group, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Clarence Powell | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |